|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||94.27 - 97.27|
|52 Week Range||84.38 - 220.20|
|Beta (5Y Monthly)||2.25|
|PE Ratio (TTM)||16.38|
|Earnings Date||Oct. 26, 2021 - Nov. 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||159.05|
On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
Any biotech acquisition is a good one -- at the right price, of course.